GE HealthCare Technologies Inc. · NASDAQ:GEHC

GE HealthCare Technologies — Q1 2023 Earnings Presentation

30 slides from GE HealthCare Technologies's earnings presentation, Apr 25, 2023

  1. Slide 1: 1Q 2023 Earnings Presentation

    1Q 2023 Earnings Presentation April 25, 2023 © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,”

  3. Slide 3: Solid Execution in 1Q'23

    Solid Execution in 1Q’23 • Double-digit growth in Organic revenue* as well as Adjusted EBIT* and Adjusted EPS* on a Standalone basis • Adjusted EBIT margin* expansion reflects positive sales price and productivity progress • Continued improvement in supply chain challenges; solid backlog; resilient

  4. Slide 4: 1Q'23 Consolidated Performance Summary

    1Q’23 Consolidated Performance Summary Revenues Adjusted EBIT* Adjusted EPS* Free cash flow* Book-to-Bill** & Adjusted EBIT margin* $4.7B $664M $0.85 $325M 1.01x 12% Organic growth*-a) 14.1% margin (11)% YoY $(46)M YoY +30bps YoY +150 bps vs prior year Up 35% vs prior year Standalone Adjusted EBIT S

  5. Slide 5: 1Q'23 Revenue Performance

    1Q’23 Revenue Performance Business Segment Products & Services** Organic revenue growth* +12%-a) Reported revenue growth +8% Ultrasound $859M, +10%*-a) Services $1.6B, +1% 33% Products $3.1B, +12% Imaging Total Revenue Total Revenue $4.7B PCS $4.7B $2.5B, +12%*-a) $781M, +11%*-a) 67% PDx $558M, +19%

  6. Slide 6: Meaningful Progress on Margin with Disciplined Pricing and Cost Actions

    Meaningful Progress on Margin with Disciplined Pricing and Cost Actions • Gross profit margin up YoY in 1Q'23 and improved sequentially from 4Q'22 due to price and productivity • Positive sales price index four quarters in a row with growth across all segments in 1Q'23 Insert logistics photo • Prior

  7. Slide 7: 1Q'23 Imaging Results

    1Q’23 Imaging Results 1Q’23 1Q’22 YoY Revenues $2,496M $2,311M 12%*-a) Segment EBIT $191M $206M (7)% Segment EBIT margin 7.7% 8.9% (120) bps Highlights • Strong Organic revenue growth* driven by MR & MI/CT due to supply chain fulfillment improvements and NPIs • EBIT margin down YoY as planned invest

  8. Slide 8: 1Q'23 Ultrasound Results

    1Q’23 Ultrasound Results 1Q’23 1Q’22 YoY Revenues $859M $815M 10%*-a) Segment EBIT $207M $192M 8% Segment EBIT margin 24.1% 23.6% 50 bps Highlights • Strong Organic revenue growth* in cardiovascular, general imaging, & women's health products, with NPIs & supply chain improvements on backlog fulfill

  9. Slide 9: 1Q'23 Patient Care Solutions Results

    1Q’23 Patient Care Solutions Results 1Q’23 1Q’22 YoY Revenues $781M $716M 11%*-a) Segment EBIT $109M $65M 68% Segment EBIT margin 14.0% 9.1% 490 bps Highlights • Strong Organic revenue growth* with improved fulfillment, supply chain resiliency actions, and price • Improved EBIT margin YoY with produ

  10. Slide 10: 1Q'23 Pharmaceutical Diagnostics Results

    1Q’23 Pharmaceutical Diagnostics Results 1Q’23 1Q’22 YoY Revenues $558M $484M 19%*-a) Segment EBIT $155M $138M 12% Segment EBIT margin 27.8% 28.5% (70) bps Highlights • Solid Organic revenue growth* driven by price and volume • EBIT margin down YoY, mainly due to raw material inflation and planned i

  11. Slide 11: 1Q'23 Free Cash Flow

    1Q’23 Free Cash Flow* Solid cash generation though impacted by new post-spin cash items • Working capital improving with collections & inventory efficiency $371M • Capex spend from continued investment on NPI and $325M capacity expansion • FCF* up YoY excluding incremental post retirement benefits &

  12. Slide 12: 2023 Outlook

    2023 Outlook 2022 2023E Organic Revenue 7% 5% to 7% Growth*-a) Adjusted EBIT 14.5% -b) 15.0% - 15.5% Margin* Standalone Adjusted ETR* 23% 23% - 25% Adjusted EPS* $3.38 -b) $3.60 - $3.75 Standalone Growth of 7%-11% FCF Conversion* 87% 85%+-c) StarGuide SPECT/CT system optimized for theranostics proce

  13. Slide 13: Investing in Future Growth

    Investing in Future Growth Imaging Ultrasound Patient Care Solutions PDx and Imaging GE HealthCare's Deep Silicon AI-powered ultrasound image detectors for a photon counting CT CARESCAPE Canvas U.S. FDA 510(k) Imaging of brain amyloid using guidance for novice users with (PCCT) (Not yet commercializ

  14. Slide 14: Summary

    Summary • Solid start to year with strong Organic revenue*, Adjusted EBIT*, and Adjusted EPS* performance on a Standalone basis • Supply chain continues to improve; progress with price, volume, and productivity, including logistics • Solid backlog across all markets • Investing in innovation to driv

  15. Slide 15: Q&A

    Q&A © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  16. Slide 16: Thank You

    Upcoming Events 2023 Virtual Annual Meeting of Stockholders May 23, 2023 Jefferies Healthcare Conference June 2023 Thank You © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  17. Slide 17: Appendix

    Appendix © 2023 GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

  18. Slide 18: Total Revenues to Organic Revenue

    Total Revenues to Organic Revenue* ($ in millions) For the three months ended March 31 Unaudited 2023 2022 % change Total revenues $ 4,707 $ 4,343 8% Less: Acquisitions(a) — — Less: Dispositions(b) — — Less: Foreign currency exchange (174) — Organic revenue* $ 4,881 $ 4,343 12 % (a) - Represents rev

  19. Slide 19: Segment Revenues to Organic Revenue

    Segment Revenues to Organic Revenue* ($ in millions) For the three months ended March 31 Unaudited 2023 2022 % change Imaging revenues $ 2,496 $ 2,311 8% Less: Acquisitions(a) — — Less: Dispositions(b) — — Less: Foreign currency exchange (98) — Imaging Organic revenue* $ 2,594 $ 2,311 12 % Ultrasoun

  20. Slide 20: Cash from Operating Activities to Free Cash Flow

    Cash from Operating Activities to Free Cash Flow* ($ in millions) For the three months ended March 31 Unaudited 2023 2022 % change Cash from (used for) operating activities – continuing operations $ 468 $ 468 —% Add: Additions to PP&E and internal-use software (143) (100) Add: Dispositions of PP&E —

  21. Slide 21: Net Income to Adjusted EBIT and Standalone Adjusted EBIT

    Net Income to Adjusted EBIT* and Standalone Adjusted EBIT* (estimate) ($ in millions) For the three months ended March 31 (Unaudited) 2023 2022 % change Net income attributable to GE HealthCare $ 372 $ 389 (4)% Add: Interest and other financial charges - net 136 4 Add: Non-operating benefit (income)

  22. Slide 22: Net Income to Adjusted Net Income and Standalone Adjusted Net Income

    Net Income to Adjusted Net Income* and Standalone Adjusted Net Income* (estimate) ($ in millions) For the three months ended March 31 (Unaudited) 2023 2022 % change Net income attributable to GE HealthCare $ 372 $ 389 (4)% Add: Non-operating benefit (income) costs (115) (2) Add: Restructuring costs(

  23. Slide 23: Diluted EPS to Adjusted EPS and Standalone Adjusted EPS

    Diluted EPS to Adjusted EPS* and Standalone Adjusted EPS* (estimate) (In dollars, except shares outstanding presented in millions) For the three months ended March 31 (Unaudited) 2023 2022 $ change Diluted earnings per share – continuing operations $ 0.41 $ 0.86 $ (0.45) Add: Deemed preferred stock

  24. Slide 24: Non-GAAP P&L Reconciliations - 1Q 2023

    Non-GAAP P&L Reconciliations - 1Q 2023 ($ in millions) Amortization Non- Acquisition, Gain/loss of Spin off and of acquisition Investment Operating Tax Effect of GAAP Restructuring disposition business Certain Tax Non-GAAP separation related revaluation benefit Reconciling Reported costs(a) related

  25. Slide 25: Supplemental Financial Estimates for 2023

    Supplemental Financial Estimates for 2023 • Organic revenue growth*-a) in the range of 5% to 7% year-over-year • Expect stronger organic growth in 1H’23 with more normalized growth in 2H’23; expect revenue dollars to Revenue grow 1H to 2H • Our current view is a foreign exchange headwind of less tha

  26. Slide 26: Acronyms

    Acronyms CT Computed Tomography FCF Free Cash Flow MI/CT Molecular Imaging and Computed Tomography MR Magnetic Resonance NPIs New Product Introductions PET/CT Positron Emission Tomography / Computed Tomography PET/MR Positron Emission Tomography / Magnetic Resonance SPECT/CT Single-Photon Emission C

  27. Slide 27: Definitions

    Definitions Sales of medical equipment, contrast agents (PDX), software licenses (excludes hosting/SaaS), Products Options and Upgrades Maintenance and repair services for equipment, training, parts, software hosting (Software as a Services Service (SaaS)) Book-to-Bill Total orders divided by total

  28. Slide 28: Non-GAAP Financial Measures

    Non-GAAP Financial Measures The non-GAAP financial measures presented in this presentation are supplemental measures of GE HealthCare’s performance and its Adjusted net income: Net income attributable to GE HealthCare excluding (1) Non-operating benefit costs; (2) liquidity that the Company believes

  29. Slide 29: Non-GAAP Financial Measures in Outlook

    Non-GAAP Financial Measures in Outlook GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow conversion based on internal forecasts that omit certain amounts that would be included

  30. Slide 30: Slide 30

GE HealthCare — Q1 2023 Earnings Presentation on 6ix